

**Amendments to the Claims:**


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (previously presented) A method of treatment of:

- i) HIV-1 infections in mammals, including humans; or
- ii) HBV infections in mammals, including humans;

which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A):



((R)-PCV-TP), or a pharmaceutically acceptable salt thereof.

Claims 2-3. (cancelled)

Claim 4. (previously presented) The method according to Claim 1 wherein the (R)-PCV-TP is in the form of a bioprecursor which is a PL-ASOR derivative, phospholipids derivative, (R)-MP Bis(POM) derivative, (R)-MP diphenyl ester derivative, or dimyristoylglycerol diphosphate derivative of (R)-PCV-MP which liberates intracellularly (R)-PCV-MP which is in turn converted to (R)-PCV-TP.

Claims 5-14. (cancelled)

Claim 15. (previously presented) The method according to Claim 1 wherein (R)-PCV-TP is in the form of a bioprecursor, which is a derivative of (R)-PCV-MP.

Claim 16. (previously presented) The method according to Claim 4 wherein the bioprecursor is a PL-ASOR derivative.

Claim 17. (previously presented) The method according to Claim 4 wherein the bioprecursor is a phospholipids derivative.

Claim 18. (previously presented) The method according to Claim 4 wherein the bioprecursor is a (R)-MP Bis(POM) derivative.

Claim 19. (previously presented) The method according to Claim 4 wherein the bioprecursor is a (R)-MP diphenyl ester derivative.

Claim 20. (previously presented) The method according to Claim 4 wherein the bioprecursor is a dimyristoylglycerol diphosphate derivative.